Editorial companion

What stands out

Bloomberg’s China Show flagged a study from Insilico that claims a drug candidate can slow or reverse aspects of biological aging, and then sat down with Insilico founder Alex Zhavoronkov to discuss building an anti-aging pipeline. That matters because this is where two big narratives meet: high-science biotech claims and the rising wave of AI-driven drug design. Investors heard a founder-level defense of the science and strategy, which is useful, but what you did not hear in a studio bite is the long, expensive road from a promising study to a safe, effective medicine for humans.